Immunotherapy in Pancreatic Cancer; the Road Less TraveledGalam Leem and Si Young Song*
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine and Yonsei Institute of Gastroenterology, Seoul, Korea
- *Corresponding Author:
- Si Young Song
MD, PhD, Division of Gastroenterology
Department of Internal Medicine
Yonsei University College of Medicine
E-mail: [email protected]
Received date: March 14, 2016; Accepted date: April 19, 2016; Published date: April 22, 2016
Citation: Leem G, Song SY (2016) Immunotherapy in Pancreatic Cancer; the Road Less Traveled. Immunol Disord Immunother 1: 106. doi: 10.4172/idit.1000106
Copyright: © 2016 Leem G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Pancreatic cancer shows extremely low responses to chemo- and radiation therapies due to its inherent genetic instability, immunosuppressive microenvironment, and the complex peritumoral stroma. They make the pancreatic cancer most lethal malignancy with 5 year survival of less than 6%, so the need of new therapeutic approaches is urgently demanded. Immunotherapies have shown promises in other multiple cancers by augmenting anti-tumor immunity, so it stood out for the alternative care of pancreatic cancer. However, up to now, immunotherapeutic agents lack efficacy in pancreatic cancer. In this review, we give an overview of immune-related therapeutic strategies, clinical trials in pancreatic cancer and current obstacles that we face. We discuss the ways to overcome those current obstacles here, and by getting over them, we hope to get over the poor prognosis of pancreatic cancer.